Infectious Disease Research
Study Title: A Study of CB-183,315 in Patients with Clostridium Difficile Associated Diarrhea (Identifier: NCT01598311).
Study Purpose: 608 patients with Clostridium Difficile Associated Diarrhea (CDAD) will participate in this study and receive either oral vancomycin or CB-183,315 in a blinded fashion. Treatment will last for 10 days and participants will be followed up for at least 40 days and a maximum of 100 days. The purpose of this study is to evaluate how well CB-183,315 treats CDAD as compared to vancomycin
Principal Investigator: Joan Duggan, M.D.
Study Coordinator: Nicole Amadio, or call for more info at 419-383-4387